Clinical response of hairy-cell leukaemia to interferon-alpha: results of an Australian study.
Twelve patients with documented, progressive hairy-cell leukaemia were treated with human lymphoblastoid interferon-alpha. All patients initially received a three-month course of interferon-alpha (3 x 10(6) U each day) which resulted in two complete remissions and 10 partial remissions. All eight patients who were dependent upon packed red-cell transfusions became independent of them and the three patients with the most severe, pretreatment pancytopenia also became independent of platelet transfusions. The histological appearance of the bone marrow improved in all patients; in three patients, a complete resolution of the leukaemic infiltrate was recorded. Adverse reactions occurred in 10 patients, but these were mild and did not interrupt treatment in seven patients. Moderate reactions that required a temporary reduction in the dose of interferon-alpha were seen in three patients. Ten patients subsequently received maintenance therapy with interferon-alpha (3 x 10(6) U, three times a week). A haematological improvement continued to be seen in all patients, and the results, with a minimum of one year of follow-up, are presented.
Royal Prince Alfred Hospital, Camperdown, NSW.
J
J
Gibson
K
K
Cameron
K
K
Gallagher
A
A
Basten
P
P
Gatenby
D
D
Joshua
H
H
Kronenberg
D000328:Adult; D000368:Aged; D001315:Australia; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D007370:Interferon Type I